Trimethaphan ( DrugBank: Trimethaphan )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
17 | Multiple system atrophy | 2 |
17. Multiple system atrophy
Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02726711 (ClinicalTrials.gov) | April 2016 | 28/1/2016 | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 | Multiple System Atrophy;Orthostatic Hypotension;Supine Hypertension | Drug: Trimethaphan;Drug: Placebo | Vanderbilt University | NULL | Active, not recruiting | 40 Years | 80 Years | All | 2 | Phase 1 | United States |
2 | NCT00179023 (ClinicalTrials.gov) | April 2003 | 13/9/2005 | The Autonomic Nervous System and Obesity | The Autonomic Nervous System and Obesity | OBESITY;HYPERTENSION;PURE AUTONOMIC FAILURE;SHY-DRAGER SYNDROME | Drug: Trimethaphan;Drug: Pseudoephedrine | Vanderbilt University | NULL | Completed | 18 Years | 80 Years | All | 128 | Phase 1 | United States |